Our unique patented gene transfer technology allows the development of numerous drug candidates for a range of different pharmaceutical applications. Our technology can be used to develop drugs for the treatment of conditions such as cancer and a range of infectious diseases. Our most advanced product is a DNA vaccine FIT-06 that we develop for treating HIV.
The engineered E2 element of the GTU® vector allows for more persistent expression of genes in both non-dividing and dividing cells. It is non-viral, which means that there is neither risk of vector replication nor integration of unwanted DNA into the patient's genome. GTU has been tested in 10 clinical trials to date. It has been found to be safe and well tolerated according to several national regulatory authorities.
Thanks to our engineered E2 element we can overcome the inherent weakness of tissue-specific promoters, enabling better expression of genes where needed. We have vectors available for a range of tissues.
Our new gtGTU(R) technology enables the expression of several new types of strong and persistent genes. Expression of, for instance a therapeutic antibody, can be sustained for up to months, challenging current therapeutic modalities.
We are concerned with the growing global problem of antibiotic resistance, and have developed a proprietary technology that allows completely antibiotic-free production of therapeutics.
Todorova B, Adam L, Culina S, Boisgard R, Martinon F, Cosma A, Ustav M, Kortulewski T, Le Grand R, Chapon C.
Sci Rep. 2017 Jun 23;7(1):4122
Read moreTodorova B, Adam L, Culina S, Boisgard R, Martinon F, Cosma A, Ustav M, Kortulewski T, Le Grand R, Chapon C.
Sci Rep. 2017 Jun 23;7(1):4122
Read moreTodorova B, Adam L, Culina S, Boisgard R, Martinon F, Cosma A, Ustav M, Kortulewski T, Le Grand R, Chapon C.
Sci Rep. 2017 Jun 23;7(1):4122
Read moreTodorova B, Adam L, Culina S, Boisgard R, Martinon F, Cosma A, Ustav M, Kortulewski T, Le Grand R, Chapon C.
Sci Rep. 2017 Jun 23;7(1):4122
Read more
